Connections: From Mima/Herellea to Acinetobacter to the Double Helix to Lwoff to … CRAB
The Weak Correlation Between Antibiotic Action and Mortality
FDA Needs Radical Reform
The Letermovir Top-Line Results are Out – Or Are They?
The CDC and Spectinomycin
GC Therapy –  Shooting for the Stars
Efficacy and Treatment Duration: Where is the Tipping Point?
QIDP, a Liberal Hand-Out from FDA
CMV Connections: Paul-Bunnell Negative Mononucleosis and ‘Changelings’
Google Search for News on “Antibiotics”
All Smiles at the Press Conference: Plazo+Levo Delivers
The Monoclonal Pursuit of the Next CMV Therapeutic
TXA-709 –  New Kid on the Block

Notice to Readers

For your information, Allphase Pharma Consulting, LLC will stop providing consultancy services for clients.and will not be posting new blogs. We appreciate your interest in our articles.  We hope we have provided a useful service to you during the last 3 Continue reading Notice to Readers

Connections: From Mima/Herellea to Acinetobacter to the Double Helix to Lwoff to … CRAB

There once was a Scientific American section authored by science historian James Burke called ‘Connections”. In it James Burke, a true renaissance man, showed us how an ‘internet’ of serendipitous encounters, connections between persons, places and events led to advances Continue reading Connections: From Mima/Herellea to Acinetobacter to the Double Helix to Lwoff to … CRAB

The Weak Correlation Between Antibiotic Action and Mortality

At the recent FDA workshop on narrow-spectrum antibiotic development[1], the concept of using bacteriological response (BR) as an efficacy endpoint was flat-out rejected. The reason given is the purported lack of correlation between BR and survival/mortality which FDA considers the Continue reading The Weak Correlation Between Antibiotic Action and Mortality

FDA Needs Radical Reform

The nomination of Dr. Scott Gottlieb for FDA commissioner, a political appointee, has created the usual bipartisan furor. He is called unqualified, a renegade, not committed enough to FDA orthodoxy, an industry darling by some and a maverick by others. All Continue reading FDA Needs Radical Reform

The Letermovir Top-Line Results are Out – Or Are They?

Usually, as development progresses from preclinical to a more advanced clinical stage, reality begins to set in: problems become apparent that were not anticipated, efficacy may be less than expected or hoped for, and the safety margins may shrink to Continue reading The Letermovir Top-Line Results are Out – Or Are They?